Silk Road Medical Reports Second Quarter 2022 Financial Results
Silk Road Medical, Inc. (Nasdaq: SILK) reported Q2 2022 revenue of $33.2 million, a 25% increase year-over-year, driven by higher TCAR adoption. Gross profit rose to $24.2 million, though gross margin slightly decreased to 73% due to manufacturing expansion costs. Operating expenses increased by 29% to $38.4 million, leading to a net loss of $15.4 million, or $0.44 per share. The company has $108.9 million in cash and projects 2022 revenue between $128 million and $133 million, reflecting 26% to 31% growth.
- Revenue increased by 25% year-over-year to $33.2 million.
- Gross profit rose to $24.2 million.
- Secured a $250 million debt facility.
- Projected 2022 revenue growth of 26% to 31%.
- Net loss increased to $15.4 million compared to $10.5 million last year.
- Operating expenses rose by 29% to $38.4 million.
SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022.
“We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a
Second Quarter 2022 Financial Results
Revenue for the second quarter of 2022 was
Gross profit for the second quarter of 2022 was
Operating expenses were
Net loss was
Cash, cash equivalents and short-term investments were
2022 Financial Guidance
Silk Road Medical projects revenue for the full year 2022 to range from
Conference Call
Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, progress made on achieving our corporate goals, and the overall strength of our business. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our filing made with the Securities and Exchange Commission in Silk Road’s Quarterly Report on Form 10-Q filing made with the Securities and Exchange Commission on May 10, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Silk Road Medical disclaims any obligation to update these forward-looking statements.
Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com
Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com
SILK ROAD MEDICAL, INC. |
Statements of Operations Data |
(unaudited, in thousands, except share and per share data) |
Three Months Ended | Six Months Ended | ||||||||||||||
June 30, | June 30, | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Revenue | $ | 33,173 | $ | 26,456 | $ | 61,193 | $ | 48,509 | |||||||
Cost of goods sold | 9,012 | 6,598 | 17,588 | 12,137 | |||||||||||
Gross profit | 24,161 | 19,858 | 43,605 | 36,372 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 10,655 | 7,261 | 18,778 | 12,744 | |||||||||||
Selling, general and administrative | 27,700 | 22,549 | 54,975 | 43,743 | |||||||||||
Total operating expenses | 38,355 | 29,810 | 73,753 | 56,487 | |||||||||||
Loss from operations | (14,194 | ) | (9,952 | ) | (30,148 | ) | (20,115 | ) | |||||||
Interest income | 122 | 47 | 134 | 142 | |||||||||||
Interest expense | (1,031 | ) | (628 | ) | (1,652 | ) | (1,250 | ) | |||||||
Loss on debt extinguishment | (245 | ) | — | (245 | ) | — | |||||||||
Other income (expense), net | (50 | ) | (6 | ) | (166 | ) | (10 | ) | |||||||
Net loss | (15,398 | ) | (10,539 | ) | (32,077 | ) | (21,233 | ) | |||||||
Other comprehensive loss: | |||||||||||||||
Change in unrealized gain (loss) on investments, net | (2 | ) | (3 | ) | (2 | ) | (36 | ) | |||||||
Net change in other comprehensive loss | (2 | ) | (3 | ) | (2 | ) | (36 | ) | |||||||
Net loss and comprehensive loss | $ | (15,400 | ) | $ | (10,542 | ) | $ | (32,079 | ) | $ | (21,269 | ) | |||
Net loss per share, basic and diluted | $ | (0.44 | ) | $ | (0.31 | ) | $ | (0.91 | ) | $ | (0.62 | ) | |||
Weighted average common shares used to compute net loss per share, basic and diluted | 35,143,178 | 34,534,099 | 35,083,569 | 34,435,812 |
SILK ROAD MEDICAL, INC. |
Balance Sheets Data |
(unaudited, in thousands) |
June 30, 2022 | December 31, 2021 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 87,637 | $ | 110,231 | |||
Short-term investments | 21,234 | — | |||||
Accounts receivable, net | 15,779 | 11,832 | |||||
Inventories | 17,616 | 17,851 | |||||
Prepaid expenses and other current assets | 4,653 | 3,412 | |||||
Total current assets | 146,919 | 143,326 | |||||
Property and equipment, net | 9,755 | 7,697 | |||||
Restricted cash | 232 | 232 | |||||
Other non-current assets | 5,815 | 5,370 | |||||
Total assets | $ | 162,721 | $ | 156,625 | |||
Liabilities and stockholders' equity | |||||||
Current liabilities | |||||||
Accounts payable | $ | 3,666 | $ | 2,379 | |||
Accrued liabilities | 17,575 | 19,802 | |||||
Short-term debt | — | 3,905 | |||||
Total current liabilities | 21,241 | 26,086 | |||||
Long-term debt | 74,033 | 44,786 | |||||
Other liabilities | 7,418 | 6,513 | |||||
Total liabilities | 102,692 | 77,385 | |||||
Stockholders' equity | |||||||
Preferred stock, | — | — | |||||
Common stock, | 35 | 35 | |||||
Additional paid-in capital | 380,775 | 367,907 | |||||
Accumulated other comprehensive income | (2 | ) | — | ||||
Accumulated deficit | (320,779 | ) | (288,702 | ) | |||
Total stockholders' equity | 60,029 | 79,240 | |||||
Total liabilities and stockholders' equity | $ | 162,721 | $ | 156,625 |
FAQ
What were Silk Road Medical's Q2 2022 earnings results?
What is Silk Road Medical's revenue guidance for 2022?
How did Silk Road Medical's gross margin change in Q2 2022?